Search
XEN-2174
go.drugbank.com/drugs/DB05012ExperimentalXEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. … NET is the primary mechanism regulating the biological effects of norepinephrine (NE) on the body.
Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
go.drugbank.com/drugs/DB15729InvestigationalLipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro. … This explains why AMSCs have been utilized in repairing craniofacial bone defects. They also have potential in treatment of scarred vocal folds.
OSI-930
go.drugbank.com/drugs/DB05913InvestigationalIn preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung cancer, glioblastoma, colorectal, renal, head and neck, non-small cell lung cancer and gastric cancers … OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors.
Tinzaparin
go.drugbank.com/drugs/DB06822ApprovedInvestigationalIt is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. … It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons.
Products: innohep 8.000 IE/0,4 ml Injektionslösung in einer Fertigspritze, innohep 10.000 IE/0,5 ml Injektionslösung in einer FertigspritzeSulfamethylthiazole
go.drugbank.com/drugs/DB15882ExperimentalSulfamethylthiazole is a sulfonamide antibacterial agent.
Synonyms: N(sup 1)-(4-Methyl-2-thiazolyl)sulfanilamide, 4-Amino-N-(4-methyl-2-thiazolyl)benzenesulfonamideCoviGlobulin
go.drugbank.com/drugs/DB15747ExperimentalCoviGlobulin, a rabbit polyclonal antibody, was specifically designed as a potential therapy for COVID-19. … The antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones.
NUC B1000
go.drugbank.com/drugs/DB05242ExperimentalOn January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection. … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid
Gluconolactone
go.drugbank.com/drugs/DB04564ApprovedGluconolactone is a naturally-occurring food additive used as a sequestrant, an acidifier, or a curing, pickling, or leavening agent. It is a cyclic ester of D-gluconic acid.